ES2331342B1 - Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones. - Google Patents

Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones. Download PDF

Info

Publication number
ES2331342B1
ES2331342B1 ES200601314A ES200601314A ES2331342B1 ES 2331342 B1 ES2331342 B1 ES 2331342B1 ES 200601314 A ES200601314 A ES 200601314A ES 200601314 A ES200601314 A ES 200601314A ES 2331342 B1 ES2331342 B1 ES 2331342B1
Authority
ES
Spain
Prior art keywords
proinsulin
nucleotide sequence
sequence
activity
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200601314A
Other languages
English (en)
Spanish (es)
Other versions
ES2331342A1 (es
Inventor
Enrique J.De La Rosa Cano
M. Flora De Pablo Davila
Patricia Boya Tremoleda
Silvia Corrochano Sanchez
Pedro De La Villa Polo
Rima Barhoum Tannous
Fatima Bosch Tubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200601314A priority Critical patent/ES2331342B1/es
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universitat Autonoma de Barcelona UAB, Universidad de Alcala de Henares UAH filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to EP07765882.1A priority patent/EP2042189B1/en
Priority to PCT/ES2007/070097 priority patent/WO2007135220A1/es
Priority to AU2007253212A priority patent/AU2007253212B2/en
Priority to ES07765882T priority patent/ES2433389T3/es
Priority to US12/227,554 priority patent/US20100330042A1/en
Priority to CA2652983A priority patent/CA2652983C/en
Priority to JP2009511534A priority patent/JP4727748B2/ja
Publication of ES2331342A1 publication Critical patent/ES2331342A1/es
Application granted granted Critical
Publication of ES2331342B1 publication Critical patent/ES2331342B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES200601314A 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones. Expired - Fee Related ES2331342B1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES200601314A ES2331342B1 (es) 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
PCT/ES2007/070097 WO2007135220A1 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones
AU2007253212A AU2007253212B2 (en) 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
ES07765882T ES2433389T3 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones
EP07765882.1A EP2042189B1 (en) 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
US12/227,554 US20100330042A1 (en) 2006-05-22 2007-05-21 Use of Proinsulin for the Preparation of a Neuroprotective Pharmaceutical Composition, Therapeutic Composition Containing it and Applications Thereof
CA2652983A CA2652983C (en) 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
JP2009511534A JP4727748B2 (ja) 2006-05-22 2007-05-21 神経保護医薬組成物の製造のためのプロインスリンの使用、それを含む治療組成物、およびそれらの応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200601314A ES2331342B1 (es) 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.

Publications (2)

Publication Number Publication Date
ES2331342A1 ES2331342A1 (es) 2009-12-29
ES2331342B1 true ES2331342B1 (es) 2010-10-13

Family

ID=38722988

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200601314A Expired - Fee Related ES2331342B1 (es) 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
ES07765882T Active ES2433389T3 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07765882T Active ES2433389T3 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones

Country Status (7)

Country Link
US (1) US20100330042A1 (https=)
EP (1) EP2042189B1 (https=)
JP (1) JP4727748B2 (https=)
AU (1) AU2007253212B2 (https=)
CA (1) CA2652983C (https=)
ES (2) ES2331342B1 (https=)
WO (1) WO2007135220A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
EP2872183B1 (en) 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2104380A (en) * 1981-08-27 1983-03-09 Lilly Co Eli Human proinsulin pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
MX9700198A (es) * 1994-07-08 1997-04-30 Dartmouth College Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.
AU8508398A (en) * 1998-07-15 2000-02-07 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2104380A (en) * 1981-08-27 1983-03-09 Lilly Co Eli Human proinsulin pharmaceutical formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CORROCHANO SÁNCHEZ, S. et al. "{}Insulina y muerte celular programada: expresión y efectos durante la neurogénesis en la retina de ratón"{}. XI Congreso de la Sociedad Española de Biología Celular. Cádiz, 3-6 Noviembre 2005. Página 90, comunicación. *
DÍAZ, B. et al. "{}Apoptotic cell death of proliferating neuroepithelial cells in the embryonic retina is prevented by insulin"{}. EUROPEAN JOURNAL OF NEUROSCIENCE. Mayo 1999. Vol. 11, N$^{o}$. 5, páginas 1624-1632; todo el documento. *
DÍAZ, B. et al. "{}In vivo regulation of cell death by embryonic (pro)insulin and the insulin receptor during early retinal neurogenesis"{}. DEVELOPMENT. 15.04.2000. Vol. 127, N$^{o}$. 8, páginas 1641-1649; todo el documento. *

Also Published As

Publication number Publication date
EP2042189B1 (en) 2013-06-26
AU2007253212A1 (en) 2007-11-29
EP2042189A1 (en) 2009-04-01
EP2042189A4 (en) 2010-02-17
US20100330042A1 (en) 2010-12-30
CA2652983A1 (en) 2007-11-29
CA2652983C (en) 2016-07-19
ES2433389T3 (es) 2013-12-10
JP4727748B2 (ja) 2011-07-20
AU2007253212B2 (en) 2012-09-27
ES2331342A1 (es) 2009-12-29
WO2007135220A1 (es) 2007-11-29
JP2009537612A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
Petters et al. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa
Hu et al. In vivo CRISPR/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa
JP4524230B2 (ja) 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
Al-Shawi et al. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development.
Wu et al. AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa
Tracy et al. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis
ES2983990T3 (es) Vectores virales que comprenden regiones codificantes de RDH12 y métodos para tratar distrofias de la retina
ES2836133T3 (es) Composiciones y métodos para modular la excitabilidad neuronal y el comportamiento motor
Palmer et al. Expression of Gtf2ird1, the Williams syndrome-associated gene, during mouse development
Stieger et al. Gene therapy for vision loss—recent developments
US20220347321A1 (en) Expression of neuropeptides
JP2022525564A (ja) アンジェルマン症候群を治療するためのベクターおよび方法
US20190125738A1 (en) Neurokinin antagonists and uses thereof
US20040224409A1 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
ES2433389T3 (es) Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones
KR100958291B1 (ko) Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법
Huang et al. Intraocular gene transfer of ciliary neurotrophic factor rescues photoreceptor degeneration in RCS rats
Vasquez et al. Replication-Deficient Adenovirus Vector Transfer ofgfpReporter Gene into Supraoptic Nucleus and Subfornical Organ Neurons
Meldrum et al. Liposomal delivery of heat-shock protein 72 into the heart prevents endotoxin-induced myocardial contractile dysfunction
Seki et al. Adenoviral gene transfer of aspartoacylase ameliorates tonic convulsions of spontaneously epileptic rats
Yokoyama et al. Genomic structure and functional characterization of NBPhox (PMX2B), a homeodomain protein specific to catecholaminergic cells that is involved in second messenger-mediated transcriptional activation
JPH09510357A (ja) 酸性繊維芽細胞成長因子（ａＦＧＦ）をコードする組み換えアデノウィルス
KR100430199B1 (ko) 칼슘 이온 통로 알파１ｄ 유전자 변이 생쥐 및 그의 제조방법
Humphries et al. Hereditary Retinopathies: Progress in Development of Genetic and Molecular Therapies
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20091229

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2331342B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211117